Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Bootman

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Evaluation & the Health Professions|May 12, 1979
Cost-benefit analysis: a research tool for evaluating innovative health programsJ L Bootman, C Rowland, A I Wertheimer
Archives of Internal Medicine|October 24, 1997
The health care cost of drug-related morbidity and mortality in nursing facilitiesJ L Bootman, D L Harrison, E Cox
American Journal of Hospital Pharmacy|April 1, 1982
Job satisfaction and the future of pharmacyM W Noel, R J Hammel, J L Bootman
American Journal of Hospital Pharmacy|May 1, 1993
Drug-use evaluation programs in short-term-care general hospitalsA K Terry, J R Draugalis, J L Bootman
Drug Intelligence & Clinical Pharmacy|March 1, 1982
Application of cost-benefit and cost-effectiveness analysis to clinical practiceJ L Bootman, W F McGhan, S W Schondelmeyer
Journal of Pharmaceutical Marketing & Management|December 10, 1988
Pharmacy participation in third-party contracts: decision making through economic and financial analysisD W Raisch, L N Larson, J L Bootman
American Journal of Hospital Pharmacy|February 1, 1978
Cost-benefit and cost-effectiveness: methodologies for evaluating innovative pharmaceutical servicesW F McGhan, C R Rowland, J L Bootman
American Journal of Hospital Pharmacy|May 1, 1982
Physician and pharmacist attitudes toward medication useJ L Bootman, P D Hurd, J A Gaines
Drug Intelligence & Clinical Pharmacy|July 1, 1984
ChymopapainT R Einarson, J L Bootman, G H Smith
British Journal of Cancer|March 21, 2015
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancerM Gharaibeh, A McBride, J L Bootman, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Evaluation & the Health Professions|May 12, 1979
Cost-benefit analysis: a research tool for evaluating innovative health programsJ L Bootman, C Rowland, A I Wertheimer
Archives of Internal Medicine|October 24, 1997
The health care cost of drug-related morbidity and mortality in nursing facilitiesJ L Bootman, D L Harrison, E Cox
American Journal of Hospital Pharmacy|April 1, 1982
Job satisfaction and the future of pharmacyM W Noel, R J Hammel, J L Bootman
American Journal of Hospital Pharmacy|May 1, 1993
Drug-use evaluation programs in short-term-care general hospitalsA K Terry, J R Draugalis, J L Bootman
Drug Intelligence & Clinical Pharmacy|March 1, 1982
Application of cost-benefit and cost-effectiveness analysis to clinical practiceJ L Bootman, W F McGhan, S W Schondelmeyer
Journal of Pharmaceutical Marketing & Management|December 10, 1988
Pharmacy participation in third-party contracts: decision making through economic and financial analysisD W Raisch, L N Larson, J L Bootman
American Journal of Hospital Pharmacy|February 1, 1978
Cost-benefit and cost-effectiveness: methodologies for evaluating innovative pharmaceutical servicesW F McGhan, C R Rowland, J L Bootman
American Journal of Hospital Pharmacy|May 1, 1982
Physician and pharmacist attitudes toward medication useJ L Bootman, P D Hurd, J A Gaines
Drug Intelligence & Clinical Pharmacy|July 1, 1984
ChymopapainT R Einarson, J L Bootman, G H Smith
British Journal of Cancer|March 21, 2015
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancerM Gharaibeh, A McBride, J L Bootman, et al.
Pageof 7